Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Dec 22
Have your own idea? Try our Stock Screener
Swiss (SMI) Biotech Industry Analysis
UpdatedDec 24, 2025
DataAggregated Company Financials
Companies4
- 7D3.2%
- 3M17.1%
- 1Y28.7%
- YTD23.7%
Over the last 7 days, the Biotech industry has dropped 2.4%, driven by Kuros Biosciences declining 4.9%. In contrast, Molecular Partners has gained 5.9%. This takes the industry's 12 month performance to a gain of 28%. Looking forward, earnings are forecast to grow by 26% annually.
Industry Valuation and Performance
Has the Swiss Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 24 Dec 2025 | CHF 2.2b | CHF 339.6m | CHF 6.5m | 9.3x | 342.6x | 6.6x |
| Fri, 21 Nov 2025 | CHF 1.8b | CHF 343.6m | -CHF 10,514,000.00 | 8.1x | -171.7x | 5.3x |
| Sun, 19 Oct 2025 | CHF 2.0b | CHF 344.3m | -CHF 15,083,000.00 | 8.1x | -134.6x | 5.9x |
| Tue, 16 Sep 2025 | CHF 1.8b | CHF 383.4m | -CHF 57,057,000.00 | 7.7x | -31.5x | 4.7x |
| Thu, 14 Aug 2025 | CHF 2.0b | CHF 333.9m | -CHF 44,705,000.00 | 8.3x | -44.3x | 5.9x |
| Sat, 12 Jul 2025 | CHF 2.0b | CHF 333.9m | -CHF 44,705,000.00 | 7.6x | -43.7x | 5.9x |
| Mon, 09 Jun 2025 | CHF 1.9b | CHF 333.9m | -CHF 44,705,000.00 | 8x | -42.1x | 5.6x |
| Wed, 07 May 2025 | CHF 1.9b | CHF 336.6m | -CHF 39,259,000.00 | 6.9x | -47.5x | 5.5x |
| Fri, 04 Apr 2025 | CHF 1.5b | CHF 409.3m | -CHF 35,110,868.00 | 4.8x | -43.6x | 3.7x |
| Sun, 02 Mar 2025 | CHF 1.8b | CHF 387.3m | -CHF 48,828,868.00 | 5.3x | -37.1x | 4.7x |
| Tue, 28 Jan 2025 | CHF 1.7b | CHF 330.3m | -CHF 75,131,868.00 | 3.1x | -22.7x | 5.2x |
| Thu, 26 Dec 2024 | CHF 1.6b | CHF 330.9m | -CHF 87,805,465.00 | 2.2x | -18.5x | 4.9x |
| Sat, 23 Nov 2024 | CHF 1.8b | CHF 331.2m | -CHF 86,988,629.00 | 1.5x | -20.2x | 5.3x |
| Mon, 21 Oct 2024 | CHF 1.8b | CHF 333.1m | -CHF 82,023,629.00 | 1.8x | -21.6x | 5.3x |
| Wed, 18 Sep 2024 | CHF 1.6b | CHF 333.6m | -CHF 81,088,264.00 | 1.7x | -19.3x | 4.7x |
| Fri, 16 Aug 2024 | CHF 810.6m | CHF 170.7m | -CHF 141,356,264.00 | 1.9x | -5.7x | 4.7x |
| Sun, 14 Jul 2024 | CHF 758.3m | CHF 151.7m | -CHF 146,197,264.00 | 1.4x | -5.2x | 5x |
| Tue, 11 Jun 2024 | CHF 624.2m | CHF 169.3m | -CHF 139,094,874.12 | 0.9x | -4.5x | 3.7x |
| Thu, 09 May 2024 | CHF 485.7m | CHF 171.0m | -CHF 134,962,367.90 | 1x | -3.6x | 2.8x |
| Sat, 06 Apr 2024 | CHF 382.6m | CHF 67.4m | -CHF 173,193,075.50 | 0.1x | -2.2x | 5.7x |
| Mon, 04 Mar 2024 | CHF 360.1m | CHF 55.6m | -CHF 173,212,672.72 | 0.2x | -2.1x | 6.5x |
| Wed, 31 Jan 2024 | CHF 377.8m | CHF 317.6m | -CHF 176,007,021.00 | 1.1x | -2.1x | 1.2x |
| Fri, 29 Dec 2023 | CHF 288.1m | CHF 317.2m | -CHF 176,181,463.00 | 0.6x | -1.6x | 0.9x |
| Sun, 26 Nov 2023 | CHF 304.1m | CHF 318.1m | -CHF 210,673,204.00 | n/a | -1.4x | 1x |
| Tue, 24 Oct 2023 | CHF 252.0m | CHF 318.1m | -CHF 212,843,042.00 | n/a | -1.2x | 0.8x |
| Thu, 21 Sep 2023 | CHF 274.7m | CHF 318.5m | -CHF 219,022,560.00 | n/a | -1.3x | 0.9x |
| Sat, 19 Aug 2023 | CHF 509.0m | CHF 325.8m | -CHF 175,785,222.00 | n/a | -2.9x | 1.6x |
| Mon, 17 Jul 2023 | CHF 315.7m | CHF 320.3m | -CHF 179,703,342.00 | n/a | -1.8x | 1x |
| Wed, 14 Jun 2023 | CHF 320.9m | CHF 333.9m | -CHF 181,118,746.00 | n/a | -1.8x | 1x |
| Fri, 12 May 2023 | CHF 369.7m | CHF 498.9m | -CHF 18,561,621.00 | 1.7x | -19.9x | 0.7x |
| Sun, 09 Apr 2023 | CHF 407.2m | CHF 485.0m | CHF 12.4m | 1.5x | 32.8x | 0.8x |
| Tue, 07 Mar 2023 | CHF 485.5m | CHF 493.4m | CHF 14.5m | 1.7x | 33.5x | 1x |
| Thu, 02 Feb 2023 | CHF 497.0m | CHF 493.4m | CHF 14.5m | 1.6x | 34.3x | 1x |
| Sat, 31 Dec 2022 | CHF 485.3m | CHF 493.4m | CHF 14.5m | 1.7x | 33.5x | 1x |
Price to Earnings Ratio
33.5x
Current Industry PE
- Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 334x which is higher than its 3-year average PE of -17.9x.
- The 3-year average PS ratio of 3.6x is lower than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 23% per year over the last three years,
- Revenues have also declined 12% per year.
- This means overall sales from these companies are declining and profits are subsequently falling as well.
Industry Trends
Which industries have driven the changes within the Swiss Healthcare industry?
| CH Market | 1.46% | |
| Healthcare | 2.50% | |
| Biotech | 3.21% | |
| Biotech | 3.21% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| IDIA Idorsia | CHF 4.43 | 12.2% +CHF 119.9m | 506.2% | PS4.8x | |
| MMTX MindMaze Therapeutics Holding | CHF 2.26 | 18.9% +CHF 54.9m | n/a | n/a | |
| BSLN Basilea Pharmaceutica | CHF 55.20 | 3.0% +CHF 19.7m | 34.1% | PE9.3x | |
| SANN Santhera Pharmaceuticals Holding | CHF 12.88 | 3.4% +CHF 5.6m | 12.6% | PS3.5x | |
| MOLN Molecular Partners | CHF 3.43 | 1.6% +CHF 2.1m | -26.0% | PB1.3x |
